Clinical Trial Update: A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) [Phase 3]

View source ↗

Summary

A 24-week open-label Phase 3 trial of KPS-0373 for Spinocerebellar Degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Degeneration

Drugs mentioned

• KPS-0373

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Spinocerebellar Degeneration | Phase 3 | Status: COMPLETED